Annual Meeting Poster Abstract Submission Rules and Format Guidelines

This document is designed to assist you in preparing your abstract for submission. Thank you for your interest in presenting at the 33rd PPA Annual Meeting. Please note that all presentations will be held in person. There are no options for virtual participation.

There are 6 categories for submission:

1. Scientific & Research
2. Innovative Case Reports
3. Best Practice
4. Scholarship of Teaching
5. Residency Projects
6. Student Research

All practitioners, investigators, post-doctoral trainees, and students in the field of pediatric clinical pharmacy, whether members of PPA or not, are invited to submit abstracts of papers to be considered for platform or poster presentation at the 33rd Annual PPA Meeting. The conference will be held on May 1 – 5, 2024 at the Hyatt Regency in Minneapolis, Minnesota.

Submission Guidelines
Poster abstracts must be completed and submitted by January 8 at 11:59 pm central; no new submissions will be accepted after this deadline. Incomplete abstracts will not be considered.

Submission Site

Primary Author
The person entering the information online is the primary author and is responsible for providing the required information to other authors. We define the “Primary Author” as the leading author and the primary presenter. The submitting author’s name will automatically appear first on the citation and the abstract, and their contact information will be printed on the published version of the abstract.

Duplicate abstracts on the same topic from one author or institution will not be accepted. Your poster presentation at the PPA Annual Meeting may not differ from the original accepted title and abstract content in your submission. It is understood that an author of the abstract will be at the meeting to present the poster.

Additional Authors:
Each submission may have up to six (6) authors – the Primary Author and 5 additional authors. The primary author is responsible to ensure that all authors are included and in the order they will appear on
the abstract and citation. PPA will not add “forgotten” authors or make changes to the order of the authors.

Meeting Registration and Cancellations
Meeting Registration
Presenting a poster at our meeting is a voluntary effort and PPA cannot pay expenses for your participation. If your submission is accepted, you are responsible for your own meeting registration fee and travel. All presenters must be registered for the meeting.

Withdrawals/Cancellations
Written notification is required for all submission withdrawals and must be submitted by the primary author. Please send your withdrawal request by to PPA Program Manager, Sandra Elery and include your full name, abstract number, and presentation title in the request. If you withdraw after receiving your acceptance notice, your presentation abstract will not appear in print, on the PPA website or other media.

Prior Publication or Presentation
Abstracts submitted for presentations must not have been presented or published previously. Exception would include those presented at an international meeting or state society meeting.

Publication Rights
PPA does not retain the exclusive rights of publication to poster abstracts submitted for our meeting.

1. All research and practice abstracts should be no longer than 450 words.
2. Research and practice abstracts will be published in the Journal of Pediatric Pharmacology and Therapeutics.
3. Platform Presentations and Best Practice Awards will be chosen from the abstracts submitted.
4. All Abstracts (except student & resident abstracts submitted in those categories) are required to have results and a conclusion to be considered for acceptance. Note: residents and students can submit abstracts in other categories, but results ARE required.

Notifications and Contact Information
Email Notifications
All correspondences including confirmations, reminders, and accept/reject notifications will be sent to the primary author’s email only. It is the primary author’s responsibility to notify the co-authors of the status of the submission. It is highly recommended that this email be a work address that is not spam protected.

Completing Your Abstract Submission
Abstract Title
- Title must accurately and concisely reflect the abstract content.
- Submission with titles that are NOT in the correct format will not be accepted.
- Only enter the title of the abstract in the title field. DO NOT put it in the abstract content field.
Title Format

- Do NOT use brand names of medications in the title.
- Capitalize only the first letter of the first word in the title, all other words must be in lowercase letters; except in the case of acronyms or proper nouns.
- Do not use “An,” “A,” or “The” as the first word in the title.
- Spell out all pharmaceutical acronyms.
- Special symbols (Mathematical signs – equals, plus, minus, percentage, greater than, less than etc.) must be spelled out.

Body of Abstract

- Your abstract will be reviewed and evaluated based on the content provided according to these guidelines.
- Word limits – the entire abstract should be no longer than 450 words.
- Proofread content carefully, particularly doses, drug names and numerical values.
- Use standard abbreviations. Do not include graphs, tables, or illustration in your abstract.
- Do not use special functions such as tabs, underlines, trademarks, superscript, subscript, bold or italics. Special symbols such as Greek letters, degrees, plus signs, minus signs or greater than or less than signs must be spelled out.
- Do not include the title or authors in the body of the abstract.

Submission Example:

ANALYSIS OF CONTINUOUS ALBUTEROL USE FOR STATUS ASTHMATICUS IN A PEDIATRIC INTENSIVE CARE UNIT: Kim Bennet, Heather Searcy, Avery Roberson. Samford University McWhorter School of Pharmacy, Birmingham, AL. kwbennet@samford.edu

Introduction: Asthma is a chronic lung disease, commonly seen in children, that can progress to status asthmaticus if untreated. Status asthmaticus can be a life threatening medical emergency which can be treated with many therapies, namely albuterol as the gold standard. Due to albuterol's ability to relax bronchial smooth muscle with subsequent dilation of the airway smooth muscle, it is often administered via intermittent or continuous nebulization. Continuous albuterol is used to treat patients presenting with status asthmaticus in the PICU. However, there is lack in data standardizing the use of continuous albuterol in the PICU setting. The purpose of this study is to analyze dosing of continuous albuterol in status asthmaticus patients.

Methods: This is a single center, retrospective chart review of patients with status asthmaticus admitted to the pediatric intensive care unit from December 2018 to June 2020 requiring at least 1 hr of continuous albuterol. Data collected includes patient demographics, continuous albuterol dose and duration, additional therapies used, and duration of PICU and hospital stay. This study was IRB approved.

Results: There were a total of 100 patients included in the data analysis. The mean age was 8.18 yrs (range 1 to 18 yrs) with 67 males (67%) and 33 African-American (33%) patients analyzed. The mean duration stay in the PICU was 63 hrs (range 9 to 262 hrs) and total hospital stay was 113 hrs (range 23 to 613 hrs). The continuous albuterol dose used ranged from 7.5 mg to 60 mg with most patients requiring 20 mg (77%). All patients (100%) received oxygen therapy and additional required medications included ipratropium (81%), magnesium (77%), ketamine (17%), and terbutaline (16%). Ninety-nine patients (99%) developed tachycardia and 64 patients (64%) developed hypokalemia while receiving continuous albuterol.

Conclusions: Continuous albuterol is used as a treatment for pediatrics with status asthmaticus at varying doses in the PICU. Further analysis of specific continuous albuterol doses relating to clinical effect such as time on oxygen and PICU stay and adverse effects will be completed in the next phase of this study.
Submission Type

Your abstract must match one of the following submission types:

1. Scientific & Research
2. Innovative Case Reports
3. Best Practice
4. Scholarship of Teaching
5. Residency Projects
6. Student Research

Research Scientific Abstracts

(Results required for all authors)

Research abstracts presented at PPA report the results of a scientific investigation or a clinical observation (case report or case series) involving some aspect of pharmacotherapy. Scientific investigations can be either clinical, basic, or translational and are either hypothesis-driven or descriptive in nature. To be accepted for presentation, research abstracts must have final results. Abstracts without results will not be accepted in this category. The abstract may be submitted in any of the following categories: Scientific and Encore Presentations (a poster that has been presented and published elsewhere. The original citation must accompany encore presentations).

All submissions will be eligible for the Young Investigator or Best Original Paper awards. The finalists will be judged by a panel of judges during the poster and platform presentation sessions. Primary authors may be considered for all awards for which they are eligible but may win only one award.

- Outstanding Original Paper: Outstanding Original Paper Investigators will be evaluated based on their written abstract and the quality of their presentation at the Meeting. The winner will receive complimentary registration to next year’s Annual Meeting and a framed certificate.
- Christensen Memorial Young Investigator Award: PPA Young Investigator Award is available to investigators who have been in practice five (5) years or less. This award will be granted to the investigator based on their written abstract and the quality of their presentation at the Meeting.

Abstracts will be reviewed based on the following criteria:
• The abstract is significant to pediatric pharmacy practice including applicability to other institutions or patients.
• The objective(s) of the research are clearly stated.
• The methods/procedures are appropriate and clearly described.
• The results are clearly and concisely presented with appropriate statistical analysis.
• The conclusions draw logically from the methods and results.

Case Report or Case Studies Presentation Abstracts
(Final Report required for ALL authors)
This year, PPA will be launching a separate Case Report/Case Studies Presentation. Current practitioners may submit their clinical observations within this category. Reports or projects are not limited to a specific research or project area but should involve some aspect of pharmacotherapy and be descriptive in nature. To be accepted for presentation, the abstract must have a final report. Case Reports will NOT be published in the Journal of Pediatric Pharmacology and Therapeutics

Abstracts will be reviewed for the following criteria:
• The abstract is significant to pediatric pharmacy practice, including applicability to other institutions or patients.
• The abstract must contain rationale detailed description of the case.
• Case Studies must contain the headings: Purpose, Methods, Results and Conclusions.
• Case Reports do not require headings.
• The work described must be complete.
• The statement “details/results will be discussed” will not be accessed.

Best Practice (Innovation in Practice) Abstracts
(Results/Outcomes REQUIRED for ALL authors)
Best and Innovative Pediatric Pharmacy Practice Abstracts typically describe programs, systems, or projects that are creative, cost-effective, and improve practice in pediatric pharmacy. Abstracts will be reviewed based on the following criteria:
• Project presented is innovative/creative and supports the advancement of pediatric pharmacy practice.
• Project presented demonstrates measurable outcomes/benefits (e.g., improved compliance, cost-effectiveness, decreased mortality)
• Project presented can be replicated at other institutions.
• Abstract is clearly and concisely written.

BPA Posters will be selected based on achievement of excellence in each of the four areas. Winners of the Best Practice Award will be chosen from accepted abstracts. The program, system, or project can be
an individual or collaborative effort in any type of practice setting, including academia, institutional, or ambulatory care.

Best Practice Abstracts should include sufficient details about the rationale, process, and hypothesis of the impact should the program, system, or project be implemented. Accepted abstracts will be published in the Journal of Pediatric Pharmacology and Therapeutics.

Submissions should include any pictures, graphs, figures and data tables that supports the summary. Each of these must be clearly labeled and described.

Scholarship of Teaching Abstracts
(Results/Outcomes REQUIRED by all Authors)

PPA will award up to two (2) Scholarship of Teaching Awards during the 33rd Annual Meeting. The awards are given to innovative and creative educational programs that advance the mission, vision, and goals of the organization. Recipients of the award receive a certificate recognizing each contributor to the program. Award recipients will share their teaching program as a poster at the Annual Meeting.

Scholarship of Teaching Abstracts describe innovative educational programs that improve pediatric pharmacy practice. Abstracts may highlight educational programs with different audiences (i.e. PharmD students, residents, patients, caregivers, pharmacists). Abstracts will be reviewed based on the following criteria:

- Project presented is innovative/creative and supports the advancement of pediatric pharmacy practice.
- Project presented demonstrates measurable outcomes/benefits (e.g., improved compliance, improved educational outcomes, increases in satisfaction scores)
- Project presented can be replicated at other institutions.
- Project presented offers improvements in knowledge, skills, and/or attitudes of the intended audience (e.g., patients, caregivers, students, residents, pharmacists)
- Abstract is clearly and concisely written.

Student Project Abstracts
(Results are not required)

Primary investigators who are currently enrolled in a BSPharm or PharmD program can submit their project within this category. Projects are not limited to a specific research or practice area. Students may submit Research-In-Progress abstracts. However, you must be able to present results during the poster session at the Annual Conference. Case Reports are accepted within the student category.

Student Investigator Award
PPA Student Investigator Award is available to primary investigators who are currently enrolled in a BSPharm or PharmD program. This award will be granted to the investigator based on their written abstract and the quality of their presentation at the Meeting. **To be considered for the award, abstracts must be submitted under the "student" category.**
Residency Project Presentation Abstracts
(Oral Presentation Only. Results are not required)

The Bruce Parks Memorial Pediatric Pharmacy Residency Presentations was established in 2006. Since its inception, the program has grown from 12 participants to nearly 200 participants in 2023. The Showcase seeks to stimulate interest in the field of pediatric pharmacy by offering an opportunity to present residency projects at the PPA Annual Conference each year. The deadline for Residency Project Presentation abstracts is extended through March 4, 2024, at 11:59 pm central time.

- Presentations are allotted 10 minutes in length followed by 5 minutes of question and answers.
- You do not need results to submit an abstract in the category.

Please note: Residency Project Abstracts are not eligible for Poster Presentation. Residents are welcome to submit a poster abstract for another project or case. If submitting under the Practice or Research categories, results are required.

Thank you for submitting your abstract for consideration, and good luck!